Vertex Pharmaceuticals (VRTX) Raw Materials (2011 - 2012)
Vertex Pharmaceuticals' quarterly Raw Materials came in at $4.5 million in Q3 2012, down 77.58% year-on-year from $20.1 million in Q4 2011, and down 11.21% quarter-over-quarter from $5.1 million in Q2 2012.
Vertex Pharmaceuticals has reported Raw Materials for 2 years, with the latest figure at $4.5 million in Q3 2012.
- For the quarter ending Q3 2012, Raw Materials fell 77.58% year-over-year to $4.5 million; the trailing twelve-month figure through Sep 2012 stood at $4.5 million (down 77.58% YoY), and the FY2011 full-year result was $32.2 million, changed N/A from the prior year.
- Raw Materials for Q3 2012 stood at $4.5 million, down from $5.1 million in the prior quarter.
- The five-year high for Raw Materials was $32.2 million in Q4 2011, with the low at $4.5 million in Q3 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 4.51 Mn |
| Jun 30, 2012 | 5.08 Mn |
| Mar 31, 2012 | 28.51 Mn |
| Dec 31, 2011 | 32.21 Mn |
| Sep 30, 2011 | 20.10 Mn |
| Mar 31, 2011 | 7.82 Mn |